Lilly execs: Net price pressures not a concern for new diabetes meds

Eli Lilly

Eli Lilly is counting on its diabetes unit to carry it to revenue growth. But don’t worry, execs told investors Friday: It can get there, and pricing pressure isn’t going to stop it.

Lilly isn’t worried about net price concerns for its newer products, diabetes VP Mike Mason said on a conference call. If there’s an area where it has any concerns at all, it’s in the “more mature” products, he said.

Take insulin Humalog, which won FDA approval 20 years ago: There, the Indianapolis drugmaker has been able to get about 1% to 2% of annual growth on net price.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

But with the company’s newer products? “I think the pressures are a little bit different than that, and we continue to get good growth,” he said.

That bodes well for SGLT2 med Jardiance, for which Lilly “anticipates net price dynamics will be less of a factor” than the overall market and market-share growth, Evercore ISI analyst Mark Schoenebaum wrote in a Friday note to clients.

And as far as market-share growth, Lilly thinks it’s sitting pretty. Last year in an outcomes trial, Jardiance showed it could lower the combined risk of heart attack, stroke and cardiovascular death in high-risk Type 2 diabetes patients--something its in-class rivals, Invokana from Johnson & Johnson and Farxiga from AstraZeneca won’t be able to do until at least 2017 and 2019, respectively.

And now, Lilly sees an update to Jardiance’s label--and an update to treatment guidelines from bodies such as the American Diabetes Association--in its future. Both of those events should offer sales boosts, it figures, especially since a label change will open the doors for Lilly’s reps to start talking up the data with docs.

“We will obviously put the right level of promotion behind that product,” execs said on the call, noting that the company has “what we need to be successful.”

- play the webcast

Special Report: 10 big brands keep pumping out big bucks, with a little help from price hikes

Related Articles:
Reduce CV events, check. Now, Lilly, BI's Jardiance shows it can cut kidney disease risk, too
Can Lilly hotshot Jardiance steam ahead if SGLT2s slow down?
Boehringer sees turbocharged diabetes unit driving future growth
Riding Q4 diabetes growth, Lilly aims for even more with Jardiance
You say you want a revolution? Lilly, BI and Jardiance may trigger one in diabetes
Lilly, BI's Jardiance posts 'amazing' 14% reduction in major CV events
In a first for diabetes, Lilly and Boehringer's Jardiance prevents heart attacks, strokes in trial

Read more on

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.